Sirtex Medical

Last week, liver cancer treatment company Sirtex reported third quarter dose sales rose 34%. That’s the largest ever increase in the number of quarterly doses sold. Importantly, dose sales in the US, which accounts for more than 60% of the company’s total, rose 47%. It’s clear that the SIR-Spheres technology is becoming increasingly accepted by the medical profession. It bodes well for revenue growth in 2012 and beyond. A few years of this sort of growth and Sirtex’s profits will explode, even taking the expensive clinical trial program into account. At the very least it suggests the company shouldn’t...

Last week, liver cancer treatment company Sirtex reported third quarter dose sales rose 34%. That’s the largest ever increase in the number of quarterly doses sold. Importantly, dose sales in the US, which accounts for more than 60% of the company’s total, rose 47%. It’s clear that the SIR-Spheres technology is becoming increasingly accepted by the medical profession.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles